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Sir,
We are grateful that Rutella et al have brought their impressive
research to our attention. We regret that we were not aware of their
work prior to the submission of our other recent publication
(Reyes E et al, 1999). As they note in their letter to the Editor,
combining our investigative results suggests that rHuG-CSF
exerts, through the induction of soluble factors such as IL-1
receptor antagonist and TNF soluble receptor, a reversible
inhibitor effect on PBMC proliferation that is not due to alterations
in cell number (CD3+, CD19+, CD45+, CD14+), cytokine produc-
tion (IL-1, IL-2, IL-6, IL-10, TNF-a, or IFNg), or activation status
(HLA-DR, CD57, or IL-2 receptor a expression). Rutella et al
suggest that the decreased PBMC proliferative response to
mitogen after treatment with sera from patients treated with rHuG-
CSF is due to cell cycle arrest such that a lymphocyte partial acti-
vation phenotype becomes dominant. Interestingly, while failure
to progress through G0 is commonly due to alterations in IL-2R
expression, we found that rHuG-CSF treatment does not alter the
expression of IL-2 receptor alpha (IL-2Ra) on PBMCs. Certainly
other avenues leading to inhibition of lymphocyte cycling will
have to be explored. Our finding of an upregulation of memory
(CD45RO+) T helper cells (CD4+) with rHuG-CSF treatment with
a concomittant decline in naive (CD4+CD45RA+) subset may
explain the decreased proliferative response to mitogens, since
naive cells demonstrate greater proliferation to mitogenic stimula-
tion than do memory cells. However, this finding cannot explain
the lymphocyte cycling arrest in G0. Evaluation of the effects of
rHuG-CSF treatment on the expression of co-regulatory molecules
on antigen presenting cells may prove fruitful in elucidating the
mechanism of lymphocyte cycling arrest.
The ability of rHuG-CSF to inhibit mitogenic proliferative
responses may be proven useful clinically in inhibiting unwanted
immunologic activity such as acute graft-versus-host disease,
autoimmune disorders, as well as chronic inflammatory diseases.
Further, Rutella et al’s suggestion that rHuG-CSF results in toler-
ance induction may be exploited by coupling rHuG-CSF treatment
with specific antigens in autoimmune disorders. Certainly, more
work is needed to establish the mechanism of rHuG-CSF’s effect
on mitogenic proliferative responses, as well as testing the effect
in the context of specific antigens. Still, the previous work of
investigators such as Rutella et al, Pan et al, and Roe et al, as well
as our own, demonstrates a fruitful role for rHuG-CSF as an
immunomodulator in the context of autoimmune/allergy and
transplant medicine.
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Sir,
We read with great interest the article of Forsyth et al (1999) (Br J
Cancer 79: 1828–1835) about the role of gene expression of
matrix metalloproteinases (MMPs) in malignant gliomas. There
is a growing interest in detecting gene expression of these
components for a better understanding of molecular mechanisms
regarding tumour invasion and metastasis in malignant diseases
(Parsons et al, 1997). Therefore, sensitive and specific molecular
biological methods are required but they are mostly user orientated
and hardly standardized.
We are investigating the molecular biology of prostate cancer, in
particular MMPs and their tissue inhibitors, by real-time RT-PCR
(Wittwer et al, 1997). Applying the primers for MMP-2 (also
named gelatinase A or collagenase IV) used by Forsyth et al for
this purpose, we experienced some disagreeable surprises which
seem important enough to us to be commented upon.1612 Letters to the Editor
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We were interested in the characteristics of Forsyth’s primer
pair and checked it by using the software ‘Primer 3’ as found
on the internet (http://www.genome.wi.mit.edu/cgi-bin/primer/
primer3_www.cgi). ‘Primer 3’ picks polymerase chain reaction
(PCR) primers amplifying a particular region of a target gene
defined from a nucleotide sequence database, generates scores for
complementarities of the primer pairs and calculates melting
temperatures and GC-contents of primers and products. Important
for that is the complete entry of mRNA sequence of the target gene
from a molecular biology database (Burks, 1999).
In the case of the MMP-2 primers from Forsyth et al, ‘Primer 3’
could not identify the binding sites of both primers in the source
MMP-2 mRNA sequence (Accession number [AC]: JO3210;
identification code [ID]: HUMCN4GEL). Putative binding sites of
both MMP-2 primers were therefore checked by a Blast-Internet
program (http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST/nph-new-
blast) comparing a nucleotide query sequence against a nucleotide
sequence database. The applied software falls back on four data-
bases (non-redundant sequences from GenBank, EMBL, DDBJ and
PDJ). To our surprise, the used MMP-2 primer sequences of
Forsyth et al produced significant alignments with regions of the
human tissue inhibitor TIMP-1 gene, exon 1 (AC: L47357; ID:
HUMTIMP1G), the human collagenease inhibitor mRNA (AC:
M59906; ID: HUMOGCA) and the human fibroblast collagenase
inhibitor mRNA (AC: M12670; ID: HUMFCI) but not with the
MMP-2 gene. However, the alignments with both collagenase
inhibitors were found only in 22 of the 25 input bases of the primers
and the Blast-program automatically cut off the first three bases.
After comparing the source mRNA sequence for both collage-
nase inhibitors mentioned above and the completed sequences of
the primers, we found one false base at the third position of the
5¢- (A instead of G) and at the 3¢-primer (C instead of A) both at
the 5¢-end. We also observed a print error in the reading direction
of the gelatinase A reverse primer (5¢ instead of 3¢). Consequently,
the size of the amplification product would be 686 bp instead of
the published product size of 473 bp.
In consequence of our investigation, we are uncertain whether the
authors really detected MMP-2 and not TIMP-1. The agarose gel
bands shown in Figure 1 cannot be considered as proof for the detec-
tion of the target gene and for the correct PCR product size since no
DNA molecular weight markers are present in the same gel run.
In addition to these data, we found that the product size for
MT1-MMP as cited in the same paper is not 548 bp but 530 bp and
that the used 5¢-primer for this gene contains a false cited base in
the third position from the 3¢-end (G instead of C).
Apart from drawing the interested reader’s attention to these
possible mistakes, the paper gives rise to the following general
recommendations:
• The selection of primers has to be documented in an easily
understandable manner to avoid serious mistakes
• Therefore, primer sequences should be specified by declara-
tion of the source of the target gene sequence (e.g. the
nucleotide sequence database used) and of the primer position
within the target sequence
• In addition, citation of the accession number (AC) and the
identification code (ID) of the investigated gene sequence
would give a definite relation between a nucleotid sequence
and its target gene.
Printing errors of nucleotide sequences of primers could thus
more easily be checked, and the suggested procedure gives a better
guarantee for correct citations and successful application of
published methods in molecular biology.
M Jung1, JM Muche2, K Jung1 and SA Loening1
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Sir,
I am replying to the above letter, which was sent concerning
our paper ‘Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and
membrane type-matrix metalloproteinase-1 (MT1-MMP) are
involved in different aspects of the pathophysiology of malignant
gliomas’, Forsyth PA et al (1999) Br J Cancer 79: 1828–1835.
Jung et al point out that the primer sequences listed in our paper
for reverse transcription polymerase chain reaction (RT-PCR)
amplification of human gelatinase-A (MMP-2) are incorrect. The
sequences given in fact correspond to primer sequences used for
human TIMP-1 amplification, with additional BamHI and HinDIII
cloning sites at the 5¢-end of the oligonucleotides to allow